[go: up one dir, main page]

IL110272A - Complex pharmaceutical preparations containing SAR inhibitors and antagonist endothelin - Google Patents

Complex pharmaceutical preparations containing SAR inhibitors and antagonist endothelin

Info

Publication number
IL110272A
IL110272A IL11027294A IL11027294A IL110272A IL 110272 A IL110272 A IL 110272A IL 11027294 A IL11027294 A IL 11027294A IL 11027294 A IL11027294 A IL 11027294A IL 110272 A IL110272 A IL 110272A
Authority
IL
Israel
Prior art keywords
preparation according
inhibitor
endothelin antagonist
ras inhibitor
methyl
Prior art date
Application number
IL11027294A
Other languages
English (en)
Hebrew (he)
Other versions
IL110272A0 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL110272A0 publication Critical patent/IL110272A0/xx
Publication of IL110272A publication Critical patent/IL110272A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
IL11027294A 1993-07-15 1994-07-11 Complex pharmaceutical preparations containing SAR inhibitors and antagonist endothelin IL110272A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH213193 1993-07-15

Publications (2)

Publication Number Publication Date
IL110272A0 IL110272A0 (en) 1994-10-21
IL110272A true IL110272A (en) 1998-07-15

Family

ID=4226611

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11027294A IL110272A (en) 1993-07-15 1994-07-11 Complex pharmaceutical preparations containing SAR inhibitors and antagonist endothelin

Country Status (25)

Country Link
US (1) US5696116A (xx)
EP (1) EP0634175B1 (xx)
JP (1) JP2746537B2 (xx)
KR (1) KR100370181B1 (xx)
CN (1) CN1105573C (xx)
AT (1) ATE198551T1 (xx)
AU (1) AU683262B2 (xx)
BR (1) BR9402815A (xx)
CA (1) CA2128142C (xx)
CZ (1) CZ285413B6 (xx)
DE (1) DE59409631D1 (xx)
DK (1) DK0634175T3 (xx)
ES (1) ES2154277T3 (xx)
GR (1) GR3035702T3 (xx)
HU (1) HU221202B1 (xx)
IL (1) IL110272A (xx)
NO (1) NO312578B1 (xx)
NZ (1) NZ260969A (xx)
PL (1) PL176445B1 (xx)
PT (1) PT634175E (xx)
RU (1) RU2146522C1 (xx)
SA (1) SA94150155B1 (xx)
TW (1) TW287949B (xx)
UA (1) UA27870C2 (xx)
ZA (1) ZA944980B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
AU717230B2 (en) 1996-02-20 2000-03-23 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
DE59810600D1 (de) * 1997-09-26 2004-02-19 Abbott Gmbh & Co Kg Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
CN1733307A (zh) * 1998-07-10 2006-02-15 诺瓦提斯公司 缬沙坦和钙通道阻断剂的抗超敏组合
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
CA2367916A1 (en) 1999-03-19 2000-09-28 Ambarish Singh Methods for the preparation of biphenyl isoxazole sulfonamides
CA2740815C (en) * 2000-08-25 2014-03-18 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
WO2004002466A1 (en) * 2002-06-28 2004-01-08 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
BRPI0413846A (pt) * 2003-08-22 2006-10-24 Schering Aktiengellschaft derivados de piperazina inibidores de quimiocina e seu uso para tratar miocardite
CA2631231A1 (en) * 2005-12-06 2007-06-14 Santen Pharmaceutical Co., Ltd. Therapeutic agent for corneal/conjuctival disease
WO2008073927A1 (en) * 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
US8071596B2 (en) 2007-01-12 2011-12-06 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018153513A1 (en) * 2017-02-27 2018-08-30 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559058A (en) * 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4470972A (en) * 1981-04-28 1984-09-11 Schering Corporation 7-Carboxyalkylaminoacyl-1,4-dithia-7-azaspiro[4.4]-nonane-8-carboxylic acids
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
DE3542794A1 (de) * 1985-12-04 1987-06-11 Bayer Ag Antihypertensives kombinationspraeparat
EP0334164B1 (de) * 1988-03-24 1993-10-27 F. Hoffmann-La Roche Ag Antihypertensives Kombinationspräparat
WO1992013545A1 (en) * 1991-01-31 1992-08-20 Abbott Laboratories Endothelin converting enzyme inhibitors
DK0498722T3 (da) * 1991-02-07 1998-03-09 Roussel Uclaf Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW216770B (xx) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists

Also Published As

Publication number Publication date
NO942650L (no) 1995-01-16
SA94150155B1 (ar) 2005-11-15
CA2128142C (en) 2007-03-06
US5696116A (en) 1997-12-09
AU6735794A (en) 1995-01-27
KR960013371A (ko) 1996-05-22
NZ260969A (en) 1996-01-26
UA27870C2 (uk) 2000-10-16
CZ285413B6 (cs) 1999-08-11
IL110272A0 (en) 1994-10-21
HU221202B1 (en) 2002-08-28
GR3035702T3 (en) 2001-07-31
ATE198551T1 (de) 2001-01-15
JP2746537B2 (ja) 1998-05-06
JPH0753408A (ja) 1995-02-28
KR100370181B1 (ko) 2003-04-26
CA2128142A1 (en) 1995-01-16
TW287949B (xx) 1996-10-11
EP0634175A1 (de) 1995-01-18
CZ167794A3 (en) 1995-01-18
AU683262B2 (en) 1997-11-06
HUT67331A (en) 1995-03-28
HU9402064D0 (en) 1994-09-28
RU94026283A (ru) 1996-05-20
CN1105573C (zh) 2003-04-16
NO312578B1 (no) 2002-06-03
EP0634175B1 (de) 2001-01-10
RU2146522C1 (ru) 2000-03-20
BR9402815A (pt) 1995-04-04
PL176445B1 (pl) 1999-05-31
PT634175E (pt) 2001-06-29
PL304292A1 (en) 1995-01-23
ZA944980B (en) 1995-02-06
ES2154277T3 (es) 2001-04-01
DE59409631D1 (de) 2001-02-15
DK0634175T3 (da) 2001-04-30
CN1107364A (zh) 1995-08-30
NO942650D0 (no) 1994-07-14

Similar Documents

Publication Publication Date Title
CA2128142C (en) Pharmaceutical combination containing ras inhibitor and endothelin antagonist for the treatment of cardiovascular disorders
RU2334513C2 (ru) Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
CA2882771C (en) Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
EP0498361A2 (en) Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor
JP2012046531A (ja) 医薬組合せ剤
JPH11503139A (ja) ベナゼプリルまたはベナゼプリラートおよびバルサルタンを含有する組み合わせ組成物
WO2005082395A1 (ja) 新規な育毛剤、抗脱毛症剤
CZ138198A3 (cs) Spojení fixní dávky inhibitoru angiotensin konvertujícího enzymu a antagonisty vápníkového kanálu, způsob pro jejich přípravu a použití v léčbě kardiovaskulárních onemocnění
US5304570A (en) Pharmaceutical composition useful for the treatment of cardiovascular diseases
RU2222328C2 (ru) Фармацевтические комбинированные препараты
RU2809222C2 (ru) Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
Januszewicz et al. Modulation of the Effect of Endothelin-3 on Blood Pressure by Atrial Natriuretic Peptide in Conscious Spontaneously Hypertensive (SHR) and Normotensive (WKY) Rats
ITTO960379A1 (it) Composizione farmaceutica per malattie cardiovascolari e renali.
MXPA00002655A (en) Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation
EP0556204A1 (en) Pharmaceutical composition containing an ace inhibitor and an inhibitor of thromboxane a2 activity for treating nephropathies
AU2007237280A1 (en) Pharmaceutical combination of Angiotensin II antagonists and Angiotensin I converting enzyme inhibitors

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired